Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7870469 | 0.85 | ALDH1A1 (0.89) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL9447521 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL1761399 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL5999214 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL9447598 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL4319368 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL5999215 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL498577 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL4280023 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL8572921 | 0.81 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023074408-A1 | THIOPHENE COMPOUND, METHOD FOR SYNTHESIZING SAME, AND COMPOSITION CONTAINING SAID THIOPHENE COMPOUND | 四国化成工業株式会社 | 2023-05-04 | — | — | WO | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| US-6312811-B1 | Photochromic naphtho [2,1-b]pyran compounds containing bithienyl or terthienyl substituents, process for their manufacture, and photochromic materials and articles obtained | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | ALDH1A1 3346/4885KDM4E 2962/4885LMNA 4352/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885KDM4E 4164/4885LMNA 1113/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885KDM4E 4164/4885LMNA 1113/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885KDM4E 4164/4885LMNA 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.